全关节置换术后氯吡格雷血栓预防:较阿司匹林增加输血风险但静脉血栓栓塞风险相似
该研究利用覆盖美国约25%住院手术的国家全支付方数据库,纳入2016至2021年行初次择期全膝关节或全髋关节置换术的成人患者,将术后接受氯吡格雷单药预防静脉血栓栓塞的患者按约1:7倾向评分匹配至接受阿司匹林单药的患者(氯吡格雷组3078例,阿司匹林组21273例)。结果显示氯吡格雷组术后输血风险(aOR 1.69;95%CI 1.30至2.21;p<0.001)和急性贫血风险(aOR 1.13;95%CI 1.03至1.26;p=0.015)高于阿司匹林组,而深静脉血栓、肺栓塞、卒中、心肌梗死、血肿或出血风险两组无显著差异。
要点
- 氯吡格雷组术后输血风险高于阿司匹林组(aOR 1.69;95%CI 1.30至2.21;p<0.001)。
- 氯吡格雷组急性贫血风险高于阿司匹林组(aOR 1.13;95%CI 1.03至1.26;p=0.015)。
- 两组深静脉血栓、肺栓塞、卒中、心肌梗死、血肿或出血风险无显著差异。
核心结论
- 术后接受氯吡格雷单药预防静脉血栓栓塞的全关节置换术患者较接受阿司匹林者术后出血并发症风险增加,但血栓栓塞并发症风险相似。
- 作者认为,对于高危心血管患者,术后恢复氯吡格雷进行血栓预防的决策应权衡其强效抗血小板活性与出血并发症风险。
研究设计与样本
- 利用覆盖美国约25%住院手术的国家全支付方医疗数据库,识别2016年至2021年间行初次择期全膝关节置换术或全髋关节置换术的成人患者。
- 将术后接受氯吡格雷单药预防静脉血栓栓塞的患者按约1:7比例倾向评分匹配至接受阿司匹林单药的患者,匹配因素包括年龄、性别、手术类型、围手术期氨甲环酸给药及已知氯吡格雷使用指征。
- 主要结局为90天出血和血栓栓塞并发症风险。
- 证据等级为治疗性III级。
主要发现
- 阿司匹林组21273例与氯吡格雷组3078例匹配,匹配后两组人口学特征、合并症、氨甲环酸给药率和医院特征无显著差异。
- 氯吡格雷组术后输血风险高于阿司匹林组(aOR 1.69;95%CI 1.30至2.21;p<0.001)。
- 氯吡格雷组急性贫血风险高于阿司匹林组(aOR 1.13;95%CI 1.03至1.26;p=0.015)。
- 两组深静脉血栓、肺栓塞、卒中、心肌梗死、血肿或出血风险无显著差异。
关键数值与推荐
- 氯吡格雷组术后输血风险aOR 1.69(95%CI 1.30至2.21;p<0.001),高于阿司匹林组。
- 氯吡格雷组急性贫血风险aOR 1.13(95%CI 1.03至1.26;p=0.015),高于阿司匹林组。
- 两组深静脉血栓、肺栓塞、卒中、心肌梗死、血肿或出血风险无显著差异(原文未报告具体数值)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing total joint arthroplasty (TJA) who are on long-term use of clopidogrel for atherothrombotic prophylaxis often continue this drug as venous thromboembolism (VTE) chemoprophylaxis following primary total knee (TKA) and total hip arthroplasty (THA). We sought to assess the 90-day bleeding and thromboembolic risk profiles of patients receiving clopidogrel monotherapy for postoperative VTE chemoprophylaxis compared with those receiving aspirin following TJA. METHODS: Utilizing a national, all-payer health-care database that captures approximately 25% of all inpatient procedures in the U.S., we identified all adult patients who underwent primary elective TKA or THA between 2016 and 2021. Patients who received clopidogrel monotherapy for postoperative VTE chemoprophylaxis were propensity-score matched in an approximately 1:7 ratio to patients who received aspirin monotherapy on the basis of age, sex, procedure type, perioperative tranexamic acid administration, and known indications for clopidogrel administration. Primary outcomes included the 90-day risks of bleeding and thromboembolic complications. RESULTS: A total of 21,273 patients who received aspirin were matched to 3,078 patients who received clopidogrel. After matching, there were no significant differences between the 2 cohorts with respect to patient demographics, comorbidities, rates of tranexamic acid administration, and hospital characteristics. After accounting for potential confounding variables, patients who received clopidogrel were at an increased risk for postoperative blood transfusion (adjusted odds ratio [aOR]: 1.69; 95% confidence interval [CI]: 1.30 to 2.21; p < 0.001) and acute anemia (aOR: 1.13; 95% CI: 1.03 to 1.26; p = 0.015) relative to patients receiving aspirin. No significant differences between the cohorts in the risk of deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, hematoma, or hemorrhage were found. CONCLUSIONS: Patients who received clopidogrel monotherapy for postoperative VTE chemoprophylaxis had an increased risk of postoperative bleeding complications but a similar risk of thromboembolic complications following TJA compared with patients who received aspirin. These findings suggest that the decision to resume clopidogrel for postoperative thromboprophylaxis should balance the potent antiplatelet activity with the risk of bleeding complications in high-risk cardiovascular patients. LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
引用
- Telang SS, Telang S, Palmer RC, et al. Postoperative Clopidogrel Thromboprophylaxis in TJA: Increased Risk of Transfusion but Similar Venous Thromboembolic Risk Compared with Aspirin. J Bone Joint Surg Am. 2025. PMID: 41460931. doi:10.2106/JBJS.25.00930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。